1197 related articles for article (PubMed ID: 25970800)
1. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
[TBL] [Abstract][Full Text] [Related]
2. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
Gottlieb AB; Kalb RE; Langley RG; Krueger GG; de Jong EM; Guenther L; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Menter A
J Drugs Dermatol; 2014 Dec; 13(12):1441-8. PubMed ID: 25607786
[TBL] [Abstract][Full Text] [Related]
3. Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics.
Ritchlin CT; Stahle M; Poulin Y; Bagel J; Chakravarty SD; Kafka S; Srivastava B; Langholff W; Gottlieb AB
BMC Rheumatol; 2019; 3():52. PubMed ID: 31799498
[TBL] [Abstract][Full Text] [Related]
4. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Menter A; Papp KA; Gooderham M; Pariser DM; Augustin M; Kerdel FA; Fakharzadeh S; Goyal K; Calabro S; Langholff W; Chavers S; Naessens D; Sermon J; Krueger GG
J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1148-58. PubMed ID: 27027388
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
[TBL] [Abstract][Full Text] [Related]
6. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Papp K; Gottlieb AB; Naldi L; Pariser D; Ho V; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Krueger G
J Drugs Dermatol; 2015 Jul; 14(7):706-14. PubMed ID: 26151787
[TBL] [Abstract][Full Text] [Related]
7. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Carretero G; Ferrandiz C; Dauden E; Vanaclocha Sebastián F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina-Gibert M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Carazo C; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):156-63. PubMed ID: 24684267
[TBL] [Abstract][Full Text] [Related]
8. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
[TBL] [Abstract][Full Text] [Related]
9. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
10. Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Singh S; Kalb RE; de Jong EMGJ; Shear NH; Lebwohl M; Langholff W; Hopkins L; Srivastava B; Armstrong AW
Am J Clin Dermatol; 2018 Dec; 19(6):879-886. PubMed ID: 30267377
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kimball AB; Guenther L; Kalia S; de Jong EMGJ; Lafferty KP; Chen DY; Langholff W; Shear NH
JAMA Dermatol; 2021 Mar; 157(3):301-306. PubMed ID: 33533924
[TBL] [Abstract][Full Text] [Related]
12. Serious infections among a large cohort of subjects with systemically treated psoriasis.
Dobry AS; Quesenberry CP; Ray GT; Geier JL; Asgari MM
J Am Acad Dermatol; 2017 Nov; 77(5):838-844. PubMed ID: 28917384
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
[TBL] [Abstract][Full Text] [Related]
14. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL
Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
[TBL] [Abstract][Full Text] [Related]
15. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
Papp KA; Strober B; Augustin M; Calabro S; Londhe A; Chevrier M;
J Drugs Dermatol; 2012 Oct; 11(10):1210-7. PubMed ID: 23134986
[TBL] [Abstract][Full Text] [Related]
16. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
Fiorentino D; Ho V; Lebwohl MG; Leite L; Hopkins L; Galindo C; Goyal K; Langholff W; Fakharzadeh S; Srivastava B; Langley RG
J Am Acad Dermatol; 2017 Nov; 77(5):845-854.e5. PubMed ID: 28893407
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N
Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307
[TBL] [Abstract][Full Text] [Related]
18. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
Becker I; Horneff G
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
[TBL] [Abstract][Full Text] [Related]
19. Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Shalom G; Naldi L; Lebwohl M; Nikkels A; de Jong EMGJ; Fakharzadeh S; Goyal KG; Srivastava B; Langholff W; Galindo C; Cohen AD
J Dermatolog Treat; 2019 Sep; 30(6):534-539. PubMed ID: 29619848
[No Abstract] [Full Text] [Related]
20. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Strober B; Gooderham M; de Jong EMGJ; Kimball AB; Langley RG; Lakdawala N; Goyal K; Lawson F; Langholff W; Hopkins L; Fakharzadeh S; Srivastava B; Menter A
J Am Acad Dermatol; 2018 Jan; 78(1):70-80. PubMed ID: 29102053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]